Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Gentamicin Alone Inadequate to Eradicate Neisseria Gonorrhoeae from the Pharynx.

Barbee LA, Soge OO, Morgan J, LeClair A, Bass T, Werth BJ, Hughes JP, Golden MR.

Clin Infect Dis. 2019 Nov 12. pii: ciz1109. doi: 10.1093/cid/ciz1109. [Epub ahead of print]

PMID:
31712813
2.

Characterization of the Mechanisms of Daptomycin Resistance among Gram-Positive Bacterial Pathogens by Multidimensional Lipidomics.

Hines KM, Waalkes A, Penewit K, Holmes EA, Salipante SJ, Werth BJ, Xu L.

mSphere. 2017 Dec 13;2(6). pii: e00492-17. doi: 10.1128/mSphere.00492-17. eCollection 2017 Nov-Dec.

3.

Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.

Werth BJ, Jain R, Hahn A, Cummings L, Weaver T, Waalkes A, Sengupta D, Salipante SJ, Rakita RM, Butler-Wu SM.

Clin Microbiol Infect. 2018 Apr;24(4):429.e1-429.e5. doi: 10.1016/j.cmi.2017.07.028. Epub 2017 Aug 3.

5.

Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.

Werth BJ, Shireman LM.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02235-16. doi: 10.1128/AAC.02235-16. Print 2017 Apr.

6.

Multidrug-Resistant Corynebacterium striatum Associated with Increased Use of Parenteral Antimicrobial Drugs.

Hahn WO, Werth BJ, Butler-Wu SM, Rakita RM.

Emerg Infect Dis. 2016 Nov;22(11). doi: 10.3201/eid2211.160141. No abstract available.

7.

Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Hall Snyder AD, Werth BJ, Nonejuie P, McRoberts JP, Pogliano J, Sakoulas G, Yim J, Singh N, Rybak MJ.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5716-23. doi: 10.1128/AAC.00687-16. Print 2016 Oct.

8.

New Guidelines Endorse Old Recommendations for Invasive Enterococcal Infections.

Werth BJ, Smith JR, Sakoulas G.

Clin Infect Dis. 2016 Jul 15;63(2):281-2. doi: 10.1093/cid/ciw286. Epub 2016 May 8. No abstract available.

PMID:
27161781
9.

Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.

Mather CA, Werth BJ, Sivagnanam S, SenGupta DJ, Butler-Wu SM.

J Clin Microbiol. 2016 Apr;54(4):883-90. doi: 10.1128/JCM.02428-15. Epub 2016 Jan 13.

10.

Emergence of High-Level Daptomycin Resistance in Corynebacterium striatum in Two Patients with Left Ventricular Assist Device Infections.

Werth BJ, Hahn WO, Butler-Wu SM, Rakita RM.

Microb Drug Resist. 2016 Apr;22(3):233-7. doi: 10.1089/mdr.2015.0208. Epub 2015 Nov 6.

11.

Differential Effects of Penicillin Binding Protein Deletion on the Susceptibility of Enterococcus faecium to Cationic Peptide Antibiotics.

Sakoulas G, Kumaraswamy M, Nonejuie P, Werth BJ, Rybak MJ, Pogliano J, Rice LB, Nizet V.

Antimicrob Agents Chemother. 2015 Oct;59(10):6132-9. doi: 10.1128/AAC.00486-15. Epub 2015 Jul 20.

12.

The combination of ampicillin plus ceftaroline is synergistic against Enterococcus faecalis.

Werth BJ, Abbott AN.

J Antimicrob Chemother. 2015 Aug;70(8):2414-7. doi: 10.1093/jac/dkv125. Epub 2015 May 7. No abstract available.

PMID:
25953804
13.

Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the United States from 1996-2010.

Werth BJ, Carreno JJ, Reveles KR.

Am J Infect Control. 2015 May 1;43(5):465-8. doi: 10.1016/j.ajic.2015.01.028. Epub 2015 Mar 14.

PMID:
25783865
14.

Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis.

Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2015 Apr;70(4):1272-3. doi: 10.1093/jac/dku480. Epub 2014 Nov 27. No abstract available.

PMID:
25433012
15.

Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.

Werth BJ, Barber KE, Tran KN, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ.

J Antimicrob Chemother. 2015 Feb;70(2):489-93. doi: 10.1093/jac/dku386. Epub 2014 Oct 9.

PMID:
25304643
16.

The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.

Barber KE, Werth BJ, Rybak MJ.

J Antimicrob Chemother. 2015 Feb;70(2):505-9. doi: 10.1093/jac/dku378. Epub 2014 Sep 22.

17.

Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes.

Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ.

J Antimicrob Chemother. 2014 Nov;69(11):3006-10. doi: 10.1093/jac/dku236. Epub 2014 Jul 1.

PMID:
24990867
18.

Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Werth BJ, Steed ME, Ireland CE, Tran TT, Nonejuie P, Murray BE, Rose WE, Sakoulas G, Pogliano J, Arias CA, Rybak MJ.

Antimicrob Agents Chemother. 2014 Sep;58(9):5253-61. doi: 10.1128/AAC.00098-14. Epub 2014 Jun 23.

19.

Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.

Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2014 Aug;69(8):2148-54. doi: 10.1093/jac/dku113. Epub 2014 Apr 28.

PMID:
24777900
21.

A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus.

Barber KE, Werth BJ, McRoberts JP, Rybak MJ.

Antimicrob Agents Chemother. 2014 May;58(5):2989-92. doi: 10.1128/AAC.02764-13. Epub 2014 Mar 10.

22.

Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the "seesaw effect": Taking advantage of the back door left open?

Ortwine JK, Werth BJ, Sakoulas G, Rybak MJ.

Drug Resist Updat. 2013 Jul-Nov;16(3-5):73-9. doi: 10.1016/j.drup.2013.10.002. Epub 2013 Oct 25.

PMID:
24268586
23.
25.

Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, Pogliano J, Rybak MJ.

Antimicrob Agents Chemother. 2013 May;57(5):2376-9. doi: 10.1128/AAC.02354-12. Epub 2013 Feb 19.

26.

Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.

Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ.

Antimicrob Agents Chemother. 2013 Jan;57(1):66-73. doi: 10.1128/AAC.01586-12. Epub 2012 Oct 15. Erratum in: Antimicrob Agents Chemother. 2013 Mar;57(3):1565.

Supplemental Content

Loading ...
Support Center